Avantel Limited: Monitoring Agency Report Confirms No Deviation in Rights Issue Proceeds Utilization
Avantel Limited's Monitoring Agency Report for the quarter ended June 30, 2026, confirms full utilization of its ₹80.91 crore Rights Issue proceeds with no deviation. The report from CARE Ratings Limited was reviewed by the Board on July 11, 2026. Minor delays in timelines were noted for certain capital expenditure objectives, with unutilized funds to be carried forward.
The announcement is a routine compliance filing regarding the utilization of funds from a past rights issue. While it confirms proper utilization, the core business operations and financial performance are not directly addressed, thus the impact is assessed as medium.
The report confirms that the company has utilized the proceeds from its rights issue as per the stated objectives, which is a positive outcome for investors and stakeholders.
Avantel Limited has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations. The report, issued by CARE Ratings Limited, confirms that the proceeds from the company's Rights Issue have been utilized for the purposes outlined in the Letter of Offer dated May 5, 2025, with no deviation or variation in utilization. The Audit Committee and the Board of Directors of Avantel Limited reviewed and took on record this report during their meetings held on July 11, 2026.
The Rights Issue, amounting to ₹80.91 crore, was for equity shares and had an issue period from May 15, 2025, to May 28, 2025. The monitoring agency report reviewed the utilization of funds towards capital expenditure for establishing a new manufacturing facility for electronics, antennas, and connectors, and for GSaaS (Ground Station as a Service) infrastructure. It also covered general corporate purposes and issue-related expenses. The total utilized amount stands at ₹76.48 crore out of the total ₹80.91 crore.
While the report confirms no deviation in the utilization of proceeds for the stated objectives, it notes a delay in the originally envisaged timelines for utilization towards certain objects. The Board had previously taken note of unutilized proceeds being carried forward for utilization during FY2026-27, as permitted by the Letter of Offer. The report from CARE Ratings Limited, dated July 11, 2026, has been submitted to BSE Limited and the National Stock Exchange of India Limited for their records.
What to do with a filing like this
Avantel Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Avantel Limited. Read the original for the full detail.